Robert W. Baird Has Lowered Expectations for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its target price reduced by Robert W. Baird from $212.00 to $210.00 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Several other research analysts have also recently commented on IQV. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Truist Financial cut their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Leerink Partners reissued an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Barclays decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Performance

Shares of IQV stock opened at $206.06 on Tuesday. The firm has a 50 day moving average of $199.41 and a two-hundred day moving average of $221.19. The stock has a market capitalization of $37.40 billion, a PE ratio of 27.04, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73.

Institutional Trading of IQVIA

Large investors have recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new position in IQVIA during the 3rd quarter worth $28,000. Avior Wealth Management LLC boosted its holdings in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Synergy Asset Management LLC purchased a new position in IQVIA during the fourth quarter worth about $33,000. Finally, Assetmark Inc. lifted its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.